Acute Coronary Syndrome Clinical Trial
— OPTICO-ACSOfficial title:
Optical Coherence Tomography in Acute Coronary Syndrome
Verified date | July 2019 |
Source | Charite University, Berlin, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The OPTICO-ACS- study program - combining for the first time in vivo characterization of the ACS-causing "culprit lesion" by intracoronary imaging technique with optical coherence tomography (OCT) and molecular analysis of immune-cells derived from the culprit coronary thrombus and biochemical analyses in patients with acute-coronary-syndrome (ACS).
Status | Active, not recruiting |
Enrollment | 414 |
Est. completion date | March 31, 2024 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: 1. Men and Women (aim: consecutive) 2. Age 18 to 85 years old. 3. ACS as trigger event - (ESC guidelines) being: 1. Acute cardiac chest pain or angina equivalent consistent with moderate to high-risk unstable angina or myocardial infarction, lasting more than 10 minutes duration during 72 hours before invasive examination AND 2. Evidence for ACS requiring catheterization documented by a) elevated enzymes (CK-MB or hs-Troponin I/T > 99th percentile or in-/decrease) AND/OR 3. ECG with ST-depression >1mm in 2 or more contiguous leads after the J-point AND/OR transient ST-elevation >1mm in 2 or more contiguous leads lasting <30 min OR c) STE-ACS with onset < 24 hours previously and chest pain >30 min ST-elevation >1mm in 2 or more contiguous leads or new left bundle block. 4. Written informed consent 5. Patients must have at least coronary one-vessel disease with one angiographically detectable "culprit lesion" (or in case of more > 1 lesion all lesions have to be in one "culprit vessel") in a native coronary vessel requiring PCI. Identification of this lesion as the "culprit lesion" has to be in line with other non-invasive findings (ECG-leads; regional wall motion abnormalities in echocardiography). Other "non-culprit-lesions" are allowed to have significant stenosis requiring interventional revascularization in a staged procedure. Exclusion Criteria: 1. Active pregnancy. 2. Active sepsis. 3. Acute psychotic disease. 4. Known systolic heart failure with left-ventricular ejection fraction (LV-EF= 30 %). 5. Cardiogenic shock or heart failure requiring intubation, inotropes; diuretics or mechanical circulation support. 6. Refractory ventricular arrhythmia requiring pharmacologic or defibrillator therapy. 7. Patients who had received heart transplantation or any other organ transplant or are on waiting list. 8. Renal insufficiency with serum-creatinine = 1.5 mg/dl. 9. Patients with other medical illness (i.e. cancer) or recent history of substance abuse, that may cause non-compliance with the investigational plan, confound the data interpretation or is associated with an anticipated limited life-expectancy less than one year. 10. Prior participation in this study or in other investigational studies, that have not reached its primary endpoint. 11. Unprotected left main- CAD with = 50% stenosis. 12. ACS with culprit lesion in a bypass graft or ACS caused by stent-thrombosis. 13. Extent and severity of CAD is such that investigator believes it is likely that bypass surgery will be required within 1 year of enrollment. 14. No suitable anatomy of "culprit lesion" for OCT: - severe calcification or extreme tortuosity of "culprit lesion". - culprit lesion with very distal location. - infarct vessels with an diameter > 4 mm or < 2 mm. - STE-ACS: "No-reflow" (TIMI 0-I) after thrombus aspiration/slight pre- dilatation |
Country | Name | City | State |
---|---|---|---|
Germany | Charite University Campus Benjamin Franklin | Berlin | |
Germany | Charite University Campus Mitte | Berlin | |
Germany | Charite University Campus Virchow-Klinikum | Berlin |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany | Berlin Institut of Health (BIH), Germany |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Major adverse cardiovascular Events (MACCE) | powered | 2 years after ACS | |
Secondary | Rehospitalization Rate for Angina pectoris | 2 years after ACS | ||
Secondary | Major adverse cardiovascular Events (MACCE) | 30 days, 90 days, 12 months and 5 years after ACS | ||
Secondary | Intima /media thickness | by sonography | Day 90 after ACS | |
Secondary | Global and regional left-ventricular systolic and diastolic function | by echocardiography | After ACS and 90 days after ACS | |
Secondary | Frequency and severity of angina | by Seattle Angina questionnaire | at day 90,12 and 24 months after ACS | |
Secondary | Pulse-wave-velocity (PWV), Augmentation index (AI) and Sub-endocardial Viability Ratio (SEVR). | by SphygmoCor system | Day 90 after ACS | |
Secondary | Lesion Coverage | by OCT | within 6 weeks to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Terminated |
NCT02620202 -
Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain
|